Pharmabiz

Nasus Pharma collaborates with Aptar to support development and commercialization of NS002

Nasus Pharma collaborates with Aptar to support development and commercialization of NS002: Tel Aviv Saturday, October 11, 2025, 12:00 Hrs [IST] Nasus Pharma Ltd, a clinical-stage ...

Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intr…

Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven ...

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

IMPORTANT SAFETY INFORMATION neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can be caused by ...

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma ...

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe ...